GLOW1: Sham (n=125); Zenkuda (n=128). GLOW2: Sham (n=125); Zenkuda (n=130). Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. p-values are based on the difference in response rates. Sight threatening complications include: diabetic macular edema, new or worsening proliferative diabetic retinopathy; anterior segment neovascularization; neovascularization of the disc and elsewhere, vitreous hemorrhage and neovascular glaucoma. Proportion of patients developing sight-threatening complications from Baseline through Week 48 GLOW1 and GLOW2 – Key Secondary Endpoint met – Zenkuda reduced the risk of developing pre-specified sight-threatening complications by ≥ 85% 15.8% 2.4% 0% 25% 50% Sham Zenkuda 21.0% 2.3% 0% 25% 50% Sham Zenkuda p<0.0001 p=0.0001 89% risk reduction 85% risk reduction GLOW1 GLOW2 5 Figure 3